Induction Therapy in the Modern Era of Combined-Modality Therapy for Locally Advanced Head and Neck Cancer

Seminars in Oncology

Volumn 35, Issue 3, 2008, Pages 221-228

  Posner, Marshall ^a   Vermorken, Jan B ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; META-ANALYSIS AS TOPIC; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SURVIVAL ANALYSIS; TAXOIDS;

EID: 44649095070     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.03.007     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. IARC. Globocan 2002. www dep.iarc.fr
3. Adelstein D., Li Y., Adams G., et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
4. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
5. Forastiere A., Maor M., Weber R., Pajak T., et al. Long term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. [abstract]. Proc Am Soc Clin Oncol (2006) 5517
6. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
7. Lefebvre J., Chevalier D., Luboinski B., Kirkpatrick A., Collette L., and Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. J Natl Cancer Inst 88 (1996) 890-898
8. Ang K.K., Harris J., Garden A.S., et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol 23 (2005) 3008-3015
9. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
10. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
11. Semrau R., Mueller R.P., Stuetzer H., et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 64 (2006) 1308-1316
12. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Physics 50 (2001) 1161-1171
13. Pignon J., Bourhis J., Domenge C., Designe L., and MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analysis of updated individual data. Lancet 355 (2000) 949-955
14. Monnerat C., Faivre S., Temam S., Bourhis J., and Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 13 (2002) 995-1006
15. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
16. Kish J., Ensley J., Jacobs J., Binns P., and Al-Sarraf M. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol 11 (1988) 553-557
17. Domenge C., Hill C., Lefebvre J., et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer 83 (2000) 1594-1598
18. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86 (1994) 265-272
19. Lefebvre J., Chevalier D., Luboinski B., et al. Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal SCC?. Final results of the phase III EORTC 24891. [abstract]. Proc Am Soc Clin Oncol 23 (2004) 5531
20. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1689
21. Lefebvre J., Horiot J., Rolland F., et al. Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemoradiotherapy in resectable hypopharynx and larynx cancers. EORTC protocol 24954-22950. [abstract]. Proc Am Soc Clin Oncol 25 (2007) LBA 6016
22. Forastiere A. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 21 Suppl 8 (1994) 49-52
23. Catimel G., Verweij J., Mattijsen V., et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5 (1994) 553-37
24. Dreyfuss A., Clark J., Norris C., et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14 (1996) 1672-1678
25. Colevas A., Busse P., Norris C., et al. Induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, and leucovorin (TPFL5) for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 16 (1998) 1331-1339
26. Colevas A., Norris C., Tishler R., et al. A phase II trial of TPFL (docetaxel, cisplatin, 5-fluorouracil, leucovorin) as induction for squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 17 (1999) 3503-3511
27. Colevas A.D., Norris C.M., Tishler R.B., et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 25 (2002) 153-159
28. Posner M.R., Glisson B., Frenette G., et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 (2001) 1096-1104
29. Schrijvers D., Van Herpen C., Kerger J., et al. Docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 15 (2004) 638-645
30. Haddad R., Colevas A.D., Tishler R., et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 97 (2003) 412-418
31. Calais G., Pointreau Y., Alfonsi M., et al. Randomized phase III trial comparing induction chemotherapy using cisplatinum, fluorouracil with or without docetaxel for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. [abstract]. Proc Am Soc Clin Oncol 24 (2006) 5506
32. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
33. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695-1704
34. Bernier J., Coens C., Remenar E., et al. Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck: EORTC study 24971. [abstract 5522]. J Clin Oncol 24 Suppl 18 (2006) 285s
35. Zorat P.L., Paccagnella A., Cavaniglia G., et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 96 (2004) 1714-1717
36. Taylor S., Murthy A., Vannetzel J., et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12 (1994) 385-395
37. Specenier P.M., and Vermorken J.B. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?. Cancer Lett 256 (2007) 166-177
38. Hitt R., Grau J., Lopez-Pousa A., et al. Randomized phase I/II clinical trial of induction chemotherapy with either cisplatin/5-fluorouracil (PF) or docetaxel/cispaltin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) v CRT alone form patients with unresectable locally advanced head and neck cancer. [abstract 5515]. J Clin Oncol 24 Suppl 18 (2006) 283s
39. Ringstrom E., Peters E., Hasegawa M., Posner M., Liu M., and Kelsey K.T. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8 (2002) 3187-3192